THIS IS AN OFFICIAL NH DHHS HEALTH ALERT

Distributed by the NH Health Alert Network <u>DHHS.Health.Alert@dhhs.nh.gov</u> January 11, 2024, 0800 (8:00 PM EDT) NH-HAN 202401111



Respiratory Virus Season Update

Key Points and Recommendations:

- NH is experiencing a high level of respiratory virus activity resulting from co-circulating high levels of influenza, COVID-19, and RSV; this is leading to <u>strain on NH hospitals</u>.
- Providers should continue to discuss and recommend immunizations for eligible patients to prevent severe disease and complications from influenza, COVID-19, and RSV. Clinical recommendations are linked below:
 - o Influenza vaccines
 - o COVID-19 vaccines
 - o RSV vaccines for adults 60 years of age and older
 - o RSV vaccine during pregnancy
 - o RSV monoclonal antibody (Nirsevimab) for infants and at-risk young children
- Real-world short-term vaccine effectiveness studies for the updated 2023-2024 COVID-19 vaccines (van Werkhoven, et al. *Euro Surveill*. Jan 2024; <u>Holm Hansen, et al. *Lancet Infect Dis.*</u> Jan 2024) found that COVID-19 vaccination reduces the risk of hospitalization from COVID-19 in older adults by about 70-75%, and can provide high-level protection when administered to coincide with times of greater COVID-19 activity during respiratory virus season.
- Providers should continue to assess patients infected with influenza or SARS-CoV-2 for outpatient treatment with oral antivirals (e.g., Tamiflu and Paxlovid, respectively).
 - o Review CDC's clinician summary on Influenza Antiviral Medications
 - o Refer to the <u>NIH COVID-19 Treatment Guidelines</u>
- <u>Numerous studies</u> (list below) have shown that early treatment with oral antivirals is effective at preventing COVID-19 related hospitalizations and deaths, especially Paxlovid which continues to be first-line outpatient therapy for treating COVID-19 in <u>high-risk persons</u> 12+ years of age.
- NH Division of Public Health Services hosts monthly webinars on the 2nd Thursday of each month from 12:00 – 1:00 pm to provide important public health updates. The next webinar will occur this Thursday, January 11th from 12:00 – 1:00 pm and respiratory virus updates will be provided:
 - o Webinar link: https://nh-dhhs.zoom.us/s/94059287404
 - o Call-in phone number: (646) 558-8656
 - Webinar ID: 940 5928 7404
 - Password: 353809
- Webinar information and updates, including past presentations, can be found at our <u>Healthcare</u> <u>Provider Resources website</u>.

Additional Information & Resources:

Multiple studies have demonstrated the effectiveness of oral antivirals Paxlovid (nirmatrelavir/ritonavir) and molnupiravir at preventing hospitalization and death in outpatients with COVID-19:

Jayk Bernal, et al. *N Engl J Med*. Feb 2022 Hammond, et al. *N Engl J Med*. Apr 2022 Arbel, et al. N Engl J Med. Sept 2022 Dryden-Peterson, et al. *Ann Intern Med*. Jan 2023 Najjar-Debbiny, et al. *Clin Infect Dis*. Feb 2023 Schwartz, et al. *CMAJ*. Feb 2023 Aggarwal, et al. *Lancet Infect Dis*. Jun 2023 Lewnard, et al. *Lancet Infect Dis*. Jul 2023 Kaboré, et al. *Clin Infect Dis*. Sept 2023 Lin, et al. *JAMA Netw Open*. Sept 2023 Faust, et al. *Clin Infect Dis*. Nov 2023

Utilize the following resources to help evaluate and manage potential Paxlovid drug-drug interactions:

- University of Liverpool: <u>COVID-19 Drug Interactions Website</u>
- NIH COVID-19 Treatment Guidelines: <u>Drug-Drug Interactions Between Ritonavir-Boosted</u> <u>Nirmatrelvir (Paxlovid) and Concomitant Medications</u>
- IDSA COVID-19 Treatment Guidelines: <u>Management of Drug Interactions with</u> <u>Nirmatrelvir/Ritonavir (Paxlovid): Resource for Clinicians</u>

- For any questions regarding this notification, please call the NH DHHS, DPHS, Bureau of Infectious Disease Control at (603) 271-4496 during business hours (8:00 a.m. 4:30 p.m.).
- If you are calling after hours or on the weekend, please call the New Hampshire Hospital switchboard at (603) 271-5300 and request the Public Health Professional on-call.
- To change your contact information in the NH Health Alert Network, please send an email to <u>DHHS.Health.Alert@dhhs.nh.gov</u> or visit <u>www.nhhan.org</u>.

Severity: Sensitivity:	Alert Moderate Not Sensitive NH-HAN 202401111
From:	Benjamin P. Chan, MD, MPH; State Epidemiologist Jonathan R. Ballard, MD, MPH; Chief Medical Officer
Originating Agency:	NH Department of Health and Human Services, Division of Public Health Services